AirNexis
airnexis.com
Actively hiring
Drug Discovery
Biotechnology
Respiratory & Sleep Devices
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
2
Longitude Capital, OrbiMed
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Longitude Capital 
OrbiMed Similar startupsby what they do, their industry and backers
Company Focus Aetherus Aetherus is dedicated to relieving breathlessness for the more than 830 million people living with it worldwide…
Scale insomnia care with NOCTEM’s RTM platform for sleep clinics and CBT-I providers. Boost capacity, adherence, and evidence-based…
Built for mission-critical moments and ease of use, Kizen empowers companies to work better, not just faster.
Nucleai helps biopharma answer two critical questions: why does a therapy work, and which patients will benefit?
Manage Consent To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to…
Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological…
News
AirNexis Announces that AN01 Met its Primary Endpoint in a Phase 2b COPD Study
The post AirNexis Announces that AN01 Met its Primary Endpoint in a Phase 2b COPD Study appeared first on AirNexis.
Read more
Report
海思科：与美国AirNexis公司签订独占许可协议最高可获9.55亿美元里程碑付款_腾讯新闻
近日海思科宣布与美国AirNexis公司签订独占许可协议授予后者在除中国大陆、中国香港特别行政区、中国澳门特别行政区及中国台湾地区以外的全球范围内开发、生产和商业化HSK39004的独家权利根据协议AirNexis将向海思科支付1.08亿美元首付款(含4000万美元现金及等值约6800万美元的AirNexis公司19.9%股权)以及最高9....
Read more
Report
AirNexis Therapeutics Launches With $200 Million Series A To Advance Phase 2 Dual PDE3/4 Inhibitor AN01 For COPD
AirNexis Therapeutics has launched as a clinical-stage biotechnology company focused on pulmonary diseases, closing a $200 million Series A financing and securing an in-license to a Phase 2 dual PDE3/4 inhibitor for chronic obstructive pulmonary disease (
Read more
Report
超10亿美元海思科与AirNexis签订独占许可协议
1月9日晚间海思科公告称公司与美国AirNexis Therapeutics, Inc.AirNexis签订独占许可协议授予AirNexis在除中国以外的全球范围内开发、生产和商业化HSK39004的独家权利本次交易构成共同投资...
Read more
Report
海思科：与AirNexis签署HSK39004项目授权许可协议_腾讯新闻
每经AI快讯1月9日海思科公告称公司与美国AirNexis Therapeutics, Inc.签订独占许可协议授予AirNexis在除中国大陆、香港、澳门及台湾地区以外的全球范围内开发、生产和商业化HSK39004的独家权利AirNexis将向海思科支付1.08亿美元首付款含4000万美元现金及等值约6800万美元的AirNexis公司19.9%股权及最高9.55亿...
Read more
Report
Jan 9, 2026 Press Releases AirNexis Launches with 200 Million Series A to Advance AN01 AirNexis acquires exclusive rights to develop AN01 outside of China from Haisco Pharmaceutical Group
AirNexis acquires exclusive rights to develop AN01 outside of China from Haisco Pharmaceutical Group
Read more
Report
海思科：与AirNexis签署HSK39004项目授权许可协议 _ 东方财富网
人民财讯1月9日电海思科(002653)1月9日公告公司与美国AirNexisTherapeutics,Inc.简称
Read more
Report
海思科与AirNexis签署HSK39004项目授权许可协议 _ 东方财富网
北京商报讯1月9日晚间海思科002653发布公告称公司与美国AirNexisTherapeutics,Inc.曾用名DragonwellBiosciences,Inc.以下简称
Read more
Report
AirNexis Therapeutics Launches with $200M Series A to Advance Phase 2 Dual PDE3/4 Inhibitor AN01 for Chronic Obstructive Pulmonary Disease (COPD)
PALO ALTO, Calif., January 09, 2026--AirNexis Therapeutics, a clinical stage biotech company developing therapeutics for pulmonary diseases, today announced the close of a $200 million Series A financing round and the in-license of a dual PDE3/4 inhibitor
Read more
Report
Show more news